Barclays Has Lowered Expectations for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its target price dropped by stock analysts at Barclays from $255.00 to $235.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price would suggest a potential upside of 17.50% from the company’s current price.

A number of other research firms have also recently commented on IQV. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday. JPMorgan Chase & Co. lowered their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Price Performance

Shares of NYSE IQV opened at $200.00 on Monday. The company has a market capitalization of $36.30 billion, a price-to-earnings ratio of 26.25, a PEG ratio of 2.15 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The business has a 50-day moving average of $200.31 and a 200-day moving average of $220.14.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pine Valley Investments Ltd Liability Co grew its stake in shares of IQVIA by 62.3% in the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 15,392 shares of the medical research company’s stock worth $3,025,000 after purchasing an additional 5,911 shares in the last quarter. Edge Capital Group LLC grew its position in IQVIA by 622.7% in the 4th quarter. Edge Capital Group LLC now owns 13,096 shares of the medical research company’s stock valued at $2,573,000 after buying an additional 11,284 shares in the last quarter. South Dakota Investment Council acquired a new position in IQVIA during the 4th quarter valued at about $2,462,000. Howard Capital Management Inc. lifted its stake in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares during the period. Finally, Abound Financial LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $512,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.